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PREVIOUS studies have shown that mast cell granules
(MCG)  inhibit  numerous  macrophage  functions
including tumour cytotoxicity, superoxide and nitric
oxide (NO) production, and FCg 2a receptor-mediated
phagocytosis.  In  this  study,  the  effect  of  MCG  on
macrophage TNFa and nitric oxide synthase (iNOS)
mRNA  expression,  and  the  production  and  fate  of
TNFa were examined. Upon activation with LPS+IFNg ,
macrophages expressed both TNFa and iNOS mRNA
and  produced both TNFa and NO. Co-incubation of
LPS+IFNg -activated macrophages with MCG resulted
in dose-dependent inhibition of iNOS mRNA expres-
sion. TNFa production in the activated macrophages
was decreased by MCG, which was associated with a
reduction in TNFa mRNA expression. MCG were also
capable of degrading both macrophage-generated and
recombinant TNFa . The direct effect of MCG on TNFa
was  partially  reversed  by  a  mixture  of  protease
inhibitors.  These  results  demonstrate  that  MCG
decrease the production of NO and TNFa by inhibiting
macrophage  iNOS  and  TNFa gene  expression.  Fur-
thermore, MCG post-transcriptionally alter TNFa lev-
els via proteolytic degradation.
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Introduction
Macrophages  play  a  major  role  in  microbicidal  and
tumoricidal  activity,  antigen  presentation,  and  the
production of a variety of cytokines and inflammatory
mediators.
1,2 Mast cells, on the other hand, play a key
role in hypersensitivity reactions by secreting media-
tors such as histamine, proteoglycans, various cyto-
kines,  metabolites  of  arachidonate  and  unique  pro-
teases.
3 –6 The recruitment of macrophages to sites of
mast cell degranulation and the subsequent phagocy-
tosis  of  granules  in  vivo was  first  reported  by
Fawcett.
7 We  have previously  shown  that  mast  cell
granules  (MCG)  interact  with  rodent  macrophages
and  downregulate  superoxide  production,
8 –10
tumour  cell  killing  and  NO  production.
11 These
reports  confirm  that  mast  cell-macrophage  commu-
nication  has  a  regulatory  effect  on  host  defence
mechanisms and inflammation. A role for mast cells in
tumour  growth  and  metastasis  is  evident  by  the
presence of an increased number of mast cells at the
periphery of certain tumours
12 –14 and by the angio-
genic  activity  of  several  mast  cell  products.
15,16
Similarly, macrophage products such as NO and TNFa
are implicated in tumour growth and inflammation.
The fact that increased number of mast cells are found
in  the  periphery  of  tumours  and  MCG  interaction
inhibited  macrophage-mediated  tumour  cell  killing
prompted us to examine the mechanism of the effect
of  MCG  on  macrophage NO and TNFa production.
The focus of this study was, therefore, to examine the
effect of MCG on mRNA expression of iNOS and TNFa
in  macrophages. The  results  demonstrate  that  MCG
interact  with  macrophages,  inhibit  iNOS  and TNFa
mRNA expression, and degrade TNFa .
Materials and methods
Materials
Lipopolysaccharide (LPS) from Escherichia coli cell
wall,  penicillin,  streptomycin,  HEPES,  metrizamide,
leupeptin, pepstatin A, aprotinin, phenylmethylsulfo-
nyl fluoride (PMSF) and thiazolyl blue dye (MTT) were
purchased from Sigma Chemical Co. (St Louis, MO).
Soybean  trypsin  inhibitor  was  purchased  from
Boehringer  Mannheim  (Indianapolis,  IN).  Heparin
solution was supplied by Elkins-Sinn, Inc. (Cherry Hill,
NJ).  Minimum  essential  medium  with  Earle’s  salts
(MEM)  and  fetal  bovine serum  were obtained  from
Hyclone Laboratories (Logan, UT). The ELISA kit for
mouse TNFa was  purchased  from  Genzyme  (Cam-
bridge, MA). Plastek M cell culture plates were from
Mat Tek Co. (Ashland, MA). The RNA Stat-60 kit was
purchased from Tel-Test, Inc. (Friendswood, TX). All
tissue culture reagents used in this study  were free
from detectable levels of endotoxin (<25pg/ml) when
tested by the limulus amoebocyte lysate gel-clot assay
(Associates of Cape Cod, Inc., Woods Hole, MA).
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Male Sprague-Dawley rats (350–400 g) used for har-
vesting  mast  cells,  and  male  C57BL/6J  mice  (2–3
months  old),  the  source  of  macrophages,  were
purchased from Harlan Co., Indianapolis, Indiana.
Harvesting and culture of murine peritoneal
macrophages
Three  days  prior  to harvesting  peritoneal exudates,
each mouse was injected intraperitoneally with 1.5 ml
of a sterile solution of proteose peptone (10% w/v).
The  peritoneal  cavity  of  each  mouse  was  lavaged
twice  with  2.5 ml  of  minimum  essential  medium
containing 15 mM HEPES, 100 units ml of penicillin,
100 m g/ml  streptomycin,  10%  fetal  bovine  serum
(HMEM) and 5 units/ml of heparin. The pooled cell
suspension was sedimented by centrifugation at 250
3 g for  10 min,  washed  twice  and  resuspended  in
HMEM without heparin. Aliquots of the cell suspen-
sion  containing 2  3 10
5 cells were seeded in  each
well  of  a  96-well  culture  plate.  Non-adherent  cells
were removed by washing after 2–4 h of incubation at
37°C. Macrophages were activated with LPS (100 ng/
ml) + IFNg (10 units/ml) in all experiments, since this
concentrations have been found to induce optimum
activation.
Isolation of mast cells
The method employed for the isolation of mast cells
has been previously described.
11,17 In brief, mast cells
were  collected  by  lavage  of  the  peritoneal  and
thoracic  cavities  of  adult  rats  with  50 ml  HMEM
containing 5 units/ml heparin. The lavaged cells from
all animals were pooled, centrifuged at 250 3 g for
10 min at room temperature, and washed twice with
HMEM. Two ml of the cell suspension containing 6–8
3 10
7 cells were gently layered on a 3 ml cushion of
22.5%  (w/v)  metrizamide  (density  1.125 g/ml)  in
HMEM in a 15 ml centrifuge tube, and centrifuged at
200 3 g for 15 min at room temperature. Mast cells
were sedimented at the bottom of the conical tube
while other cells (predominantly  macrophages) col-
lected at the interface. The mast cell fractions were
collected, washed twice, and resuspended in HMEM
without  heparin.  Purity  and  viability  of  mast  cells
isolated by this procedure exceeded 95%.
Preparation of MCG and MCG sonicate
Under  sterile  conditions  at  0–4°C,  MCG  were  pre-
pared  from metrizamide-purified  mast  cells  by  con-
trolled  sonication  and  sucrose  gradient  centrifuga-
tion. Mast cells were suspended in 1 ml of HMEM and
sonicated  twice  for  20s  with  a  microtip  sonicator
(Sonifier  Cell  Disruptor,  model W140)  at  a  power
setting  of  2.5  and  temperature  of  4°C.
9,18 The
disrupted cells were incubated at 30°C for 15min and
mixed vigorously for 1 min. The sonicate was layered
on 2 ml of 0.34 M sucrose and centrifuged at 50 3 g
for 10min at 4°C. The granules at the interface were
collected and sedimented by centrifugation at 1800 3
g for 20 min at 4°C. The resulting pellet consisting of
a  homogeneous  preparation  of  MCG  was  washed
twice and  resuspended in  the culture medium. The
recovery  of  granules  isolated  by  this  procedure
ranged  from  60%  to  80%  based  on  the  histamine
content of the starting mast cells.
MCG-sonicate was prepared by sonicating purified
MCG  in  HMEM  three  times  for  30 s  at  maximum
power. The quantity of MCG and MCG-sonicate used
in each experiment was expressed as the equivalent
of the starting mast cell number.
Assay of TNFa
The  concentration  of TNFa in  the  culture  medium
was assayed by both ELISA and bioassay. The sensitiv-
ity  of  ELISA  is  31 pg/ml  using  the  protocol  recom-
mended  by  the  manufacturer.  For  the  bioassay,  the
target L929 cells in RPMI-1640 medium were seeded
(4.2 3 10
4 per well) in a 96-well culture plate. After
18 h of culture, medium was replaced with 5 m g/ml of
dactinomycin  in  RPMI. Two  to  4 h  after  incubation
with dactinomycin, serially diluted samples and TNFa
standards (2–250 pg/ml) were added and  incubated
for  an  additional  18–24 h.  The  medium  was  then
removed, and 1 mg/ml of MTT dye in RPMI (without
serum  and  phenol  red)  was  added. After  2–3 h  of
incubation,  the  medium  was  aspirated  completely,
and 100 m l of 2-propanol was added to each well. The
plate was agitated for 10 min on an orbital shaker and
read on a microtitre plate reader at 595 nm.
Analysis of iNOS and TNFa mRNA expression
Mouse peritoneal cells which contained >85% macro-
phages  were  seeded  in  a  10cm  Petri  dish  and
incubated for 4 h to allow for macrophage adherence.
After washing three times with HMEM, the cells were
treated with MCG and activated with LPS + IFNg . At
selected time points after activation, culture medium
was removed, and the total cellular RNA was extracted
using an RNA extraction  kit. Total RNA (10 m g) was
electrophoresed  on  0.8%  agarose-formaldehyde  gel
and then transferred to Nytran nylon membrane. After
2 h of prehybridization, the membrane was hybridized
with 
32P-labelled  cDNA  probe  specific  for  murine
iNOS, TNFa or b -actin. The probes were labelled by
random hexamer priming method using [a -
32P] dCTP
as previously described.
19 The membrane  was  then
washed four times and autoradiographed on a Kodak
X-OMAT-AR film. A scanner was used to determine the
density of the mRNA band and the relative density of
each band was normalized to b -actin.
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MCG  were  incubated  with  a  mixture  of  protease
inhibitors  containing  PMSF  2.5 mM,  pepstatin  A
5 m g/ml,  trypsin  inhibitor  50 m g/ml,  leupeptin
50 m g/ml, and aprotinin 50 m g/ml, at 37°C for 2 h. The
protease inhibitor-treated MCG were then evaluated
for their effects on macrophages.
Statistical analysis
Whenever applicable, the data were analysed by one-
way  analysis  of  variance  with  subsequent  Student-
Newman-Kuels’  test.  All  results  were  expressed  as
means ± SEM and P<0.05 was considered significant.
Results
Effects of MCG on macrophage iNOS mRNA
expression
Earlier work demonstrated that MCG inhibit  macro-
phage  NO  production.
11 To  investigate  the  mecha-
nism, the effect of MCG on macrophage iNOS mRNA
expression  was  analysed  at  selected  mast  cell-to-
macrophage ratios. The addition  of MCG  simultane-
ously  with  LPS+IFNg to  macrophage  monolayer
inhibited iNOS mRNA expression in a dose-dependent
manner (Fig. 1). Maximal  inhibition  was noted at  a
MCG  dose  equivalent  to  a  mast  cell-to-macrophage
ratio of 1:5 and the inhibition was evident even at a
ratio of 1:40. When macrophages were pre-incubated
with MCG for 3 h prior to activation, the inhibitory
effect of MCG  decreased compared with  simultane-
ous addition of MCG and the activators. Furthermore,
if macrophages were incubated with MCG for more
than 6 h prior to activation, there was no inhibition of
the expression of iNOS transcript (Fig. 2).
Effects of MCG on TNFa production
When  activated  with  LPS+IFNg ,  macrophages  gen-
erated large amounts of TNFa . Addition  of  MCG  or
MCG-S at the time of LPS+IFNg stimulation resulted in
dose-dependent  decrease  in TNFa levels  and  more
than  a  90%  decrease  was  noted  at  a  MCG  dose
equivalent to a mast cell-to-macrophage ratio of 1.5 to
2 (Fig. 3). The MCG-induced decrease in TNFa levels
was seen when determined by ELISA (Fig. 3A) and by
bioassay  (Fig.  3B). Although  the  assayed  values  dif-
fered for the same samples depending on the assay
method employed, the decrease of TNFa levels was
evident. There  was  no  statistically  significant  differ-
ence  between  the  effects  of  MCG  and  MCG-S.
Therefore, in later experiments only the intact MCG
were  used.  Unactivated  macrophages  or  those
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FIG. 1. Effect of MCG on macrophage iNOS mRNA expres-
sion. Adherent macrophages (1 3 107) were exposed to the
indicated doses of MCG (mast cell equivalent) and activated
with LPS (100ng/ml) + IFNg (10units/ml). In all subsequent
experiments  the  macrophages  were  activated  with  these
concentrations. Eighteen  hours  after activation, iNOS and
b -actin  mRNA  were  analysed  by  Northern  blotting.  The
b -actin expression was used to normalize the data. For top
panel: lane 1. control; lane 2. LPS+IFNg ; lane 3. LPS+IFNg
+MCG  23 106;  lane  4.  LPS+IFNg +MCG  13 106;  lane  5.
LPS+FNg +MCG 0.53 106; lane 6. LPS+IFNg +MCG 0.253 106.
This is representative of three experiments.
FIG. 2. Effect of pre-treatment of macrophages with MCG on
iNOS  mRNA  expression.  Macrophages  (1  3 107)  were
cultured with MCG (2 3 106 mast cell equivalent) for 24, 6
and 3h prior to activation or added simultaneously with LPS
+ IFNg . Eighteen  hours  after activation, iNOS and  b -actin
mRNA  were  analysed  by  Northern  blotting.  The  b -actin
expression was used to normalize the data. This is repre-
sentative of three experiments.exposed  only  to  MCG  or  MCG-S  did  not  produce
detectable levels of TNFa .
The  production  of  TNFa by  macrophages  was
evident  as early  as 1.5 h after activation. The cumu-
lative TNFa level increased for up to 24 h while the
rate of production appeared to decrease (Fig. 4). The
presence  of  MCG  decreased  the  level  of TNFa by
approximately 40% at 1.5 and 6 h in contrast to a 95%
decrease at 24 h. This effect was also evident when
TNFa was assayed by bioassay (data not shown).
Effects of MCG on TNFa mRNA expression
In order to assess the effect of MCG on TNFa mRNA
expression by activated macrophages, the transcripts
were  analysed  at  2,  6  and  24 h  of  incubation  after
activation. The result demonstrates that TNFa mRNA
was rapidly expressed to a maximal level within 2 h
after activation and then declined thereafter (Fig. 5).
Addition  of  MCG  to  LPS+IFNg -stimulated  macro-
phages inhibited TNFa mRNA expression by 60% at a
mast cell-to-macrophage ratio of 1:3.
Effect of MCG proteases on TNFa degradation
Rat mast cell granules contain a variety of proteases
including  tryptase,  chymase,  and  carboxypepti-
Y. Li et al.
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FIG. 3. Dose response effect of MCG or MCG-S on macro-
phage  TNFa production. Adherent  macrophages (200,000)
were cultured with LPS + IFNg in the presence or absence of
the indicated doses of MCG or MCG-S (mast cell equivalent).
After 6h of culture, media were collected and TNFa levels
were measured by ELISA (panel A) and bio-assay (panel B)
utilizing L929 cells as the target. Each value presented is the
mean ± SEM of quadruplicate determinations. There is no
significant difference between the effects of MCG and MCG-
S. This is representative of three experiments.*P<0.05 vs. no
MCG added.
FIG. 4. Time course of the effect of MCG on macrophage
secreted TNFa levels. Adherent macrophages (200,000) were
cultured with LPS + IFNg in the presence or absence of MCG
(100000 mast cell equivalent). After the indicated times, media
were collected and TNFa levels were measured by ELISA.
Each value presented is the mean ± SEM of quadruplicate
determinations.  This  is  representative  of  two  experi-
ments.*P<0.05 vs. LPS+IFNg only at the same time point.
FIG. 5. Effect of MCG on macrophage TNFa mRNA expres-
sion. Macrophages (1.5 3 107) were cultured without or with
MCG  (5  3 106 mast  cell  equivalent)  and  simultaneously
activated with LPS + IFNg . After the indicated culture times,
TNFa and b -actin mRNA were analysed by Northern blotting.
The b -actin expression was used to normalize the data. This
is representative of three experiments.dase.
20 –23 To  investigate  if  TNFa is  susceptible  to
these enzymes, conditioned media with known levels
of  TNFa from  LPS+IFNg -activated  macrophages  or
recombinant mouse TNFa were incubated with MCG
for 24 h at 37°C. The TNFa levels, assayed by ELISA,
indicate  that  both  recombinant  and  macrophage-
secreted TNFa were degraded by MCG (Fig. 6). This
effect was partially reversed by the pre-treatment of
MCG with a mixture of protease inhibitors containing
PMSF,  pepstatin  A,  trypsin  inhibitor,  leupeptin  and
aprotinin (Fig. 7). The complete abrogation of TNFa
degradation by MCG could not be achieved even after
extending  the  pre-treatment  of  MCG  with  these
protease inhibitors to 24 h at 4°C.
Discussion
The  present  study  demonstrates  that  incubation  of
macrophages  with  MCG  during  activation  with
LPS+INFg results in the inhibition of iNOS and TNFa
mRNA expression with a consequent decrease in NO
and TNFa production. This corroborates our previous
report  documenting MCG inhibition of NO produc-
tion  and  tumour  cell  killing  by  LPS+INFg -activated
macrophages.
11 The MCG effect was evident even at
an estimated mast cell to macrophage ratio of 1:40, a
relationship  likely  to  occur  in  vivo. The  inhibitory
effect of MCG  on  macrophage iNOS  mRNA expres-
sion  seems  transient  because  this  effect  disappears
when  the  macrophages  were  pre-incubated  with
MCG  for  6 h  or  more. The  same  phenomenon  was
observed with the inhibitory effect of MCG on TNFa
mRNA  expression  (data  not  shown).  Our  earlier
studies have ruled out the possibilities that MCG may
inactivate LPS or IFNg . Further investigation is needed
to  clarify  the  mechanism  by  which  MCG  inhibit
macrophage iNOS and TNFa mRNA expression in a
transient manner.
The expression of TNFa by activated macrophages
is of particular significance since the genes encoding
iNOS and TNFa can be coordinately regulated. In vivo
studies have suggested a role for TNFa in the positive
regulation of iNOS following LPS injection. Anti-TNFa
antibodies  or  soluble  TNFa receptor  antagonists
partially block LPS-induced pulmonary iNOS activity
or hepatic iNOS mRNA  expression respectively.
24,25
Furthermore, the  involvement  of TNFa in  both  the
induction and maintenance of iNOS mRNA in macro-
phages was recently reported using an in vivo mouse
model.
26 These  studies  indicate  that  TNFa is  an
autocrine  regulator  of  iNOS  expression. The TNFa
mRNA expression begins as early as 0.5 h,
27 whereas
iNOS  mRNA  cannot  be  detected  until  8 h  after
activation.
28 Our  data  also  show  that TNFa mRNA
expression  by  macrophages  is  optimal  at  2 h  after
activation and then progressively decreases. Based on
those data we conclude that the depletion of macro-
phage-secreted TNFa by  MCG  could  contribute  to
inhibition of LPS-induced iNOS mRNA expression. It
is  clear  that  the  MCG  to  macrophage  ratio  that
completely  inhibits  the  expression  of  iNOS  mRNA
only partially inhibits the expression of TNFa mRNA.
We do not yet have an explanation for this phenom-
enon. It is possible that the iNOS expression needs a
finite amount of TNFa to trigger the gene.
Rodent  mast  cells  contain  histamine,  serotonin,
and  proteases  including  serine  proteases,  neutral
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FIG. 6. TNFa degradation by MCG. Macrophage derived and
recombinant TNFa were incubated with MCG (100,000 mast
cell equivalent) in a volume of 0.2ml culture medium for
24h. TNFa was assayed by ELISA. Values presented are the
mean  ±  SEM  of  quadruplicate  determinations.  This  is  a
representative of four experiments.*P<0.05 vs. no MCG.
FIG. 7. Effect of protease inhibitors on TNFa degradation by
MCG.  Mouse  recombinant  TNFa was  incubated  with  the
indicated doses of MCG in cell culture medium for 24h. MCG
were incubated with the protease inhibitor mixture at 37°C
for 2h before being added to TNFa . The TNFa levels were
assayed by ELISA. Values presented are the mean ± SEM of
quadruplicate  determinations. The protease inhibitor mix-
ture contains  2.5mM PMSF, 5m g/ml pepstatin A, 50m g/ml
each  of  trypsin  inhibitor, leupeptin  and  aprotinin.  This  is
representative of three experiments.*P<0.05 vs. control.proteases,  and  carboxypeptidase  A.
20–23 Histamine
and  serotonin  at  concentrations  present  in  mast
cells (20 m g and  2 m g per million cells respectively)
may  induce  immunomodulatory  effects.  For
instance, histamine up-regulates macrophage synthe-
sis  of  IL-1.
29 However,  histamine  at  concentrations
in  the range of 10
–6–10
–3 M (equalling and  exceed-
ing  that  present  in  MCG  used  in  this  study)  failed
to affect TNFa and NO production by macrophages
(data  not  shown). These  results  are  in  agreement
with our earlier report of MCG inhibition of macro-
phage  superoxide  production,  which  showed  that
unlike  MCG,  histamine  and  serotonin  were  ineffec-
tive in modulating the respiratory burst.
9 The effect
of serotonin on macrophage NO and TNFa was not
tested  in  this  study.  It  is  also  noteworthy  that
histamine  and  serotonin  are  short-lived  and  their
effects are rapidly lost after mast cell degranulation.
Heparin  is  an  important  constituent  of  MCG  and
murine macrophages possess heparin receptors.
30 A
previous report has shown that commercial heparin
and  MCG  are  capable  of  inhibiting  Fcg 2a  receptor
mediated  phagocytosis  in  macrophage  cell  line.
31
Although commercial heparin differs from rat MCG-
heparin,  it  is  possible  that  MCG-heparin  may  have
some  modulatory  effects  on  macrophage  iNOS  and
TNFa expression.  Our  results presented here show
that  both  MCG  and  MCG-sonicate  are  capable  of
degrading TNFa with  loss  of  immunoreactivity  and
biological  activity,  and  that  both  secreted  and
recombinant  TNFa are  susceptible.  This  indicates
that the decreased levels of TNFa could be partially
due  to the  proteolytic  effects  of  MCG-proteases,  in
addition  to  the  effect  of  MCG  inhibition  of  macro-
phage TNFa mRNA  expression.  However,  this  pro-
teolytic  effect  was  only  partially  reversed  by  treat-
ment of MCG with a mixture of protease inhibitors.
The  failure  of  protease  inhibitors  to  completely
abrogate the MCG effect may be due to incomplete
inhibition  of  the  protease  activity  or  due  to  the
absence  of  specific  inhibitors  for  certain
proteases.
Mast cell degranulation generates the release of a
variety of inflammatory molecules that directly stim-
ulate  many  cell  types  including  epithelial  cells,
32
fibroblasts
33 and endothelial cells.
17 This study is the
first evidence that  mast cell granules inhibit  macro-
phage TNFa and  iNOS  mRNA  expression. We  also
found that the mast cell proteases degrade recombi-
nant  and  macrophage  secreted TNFa . The  pre-  and
post-transcriptional regulation of TNFa production in
LPS-activated macrophages by MCG may contribute to
the inhibition of iNOS mRNA expression.
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